3D Signatures' Teloview Software Identifies and Stages Patients with Alzheimer's Disease from a Cheek Swab

Life Science Investing News
Company News

WINNIPEG, MB (March 21, 2017) − 3D Signatures Inc.(TSXV:DXD) (the “Company” or “3DS”), is pleased to announce clinical study results which confirm that based on a swab from the inside of a patient’s cheek, its proprietary TeloViewTM software platform has the ability to identify patients with Alzheimer’s disease (“AD”) and, furthermore, distinguish between mild, moderate, …

WINNIPEG, MB (March 21, 2017) − 3D Signatures Inc.(TSXV:DXD) (the “Company” or “3DS”), is pleased to announce clinical study results which confirm that based on a swab from the inside of a patient’s cheek, its proprietary TeloViewTM software platform has the ability to identify patients with Alzheimer’s disease (“AD”) and, furthermore, distinguish between mild, moderate, and severe forms of the disease. The results of this confirmatory study have been accepted for publication in the peer-reviewed Journal of Alzheimer’s Disease.

AD is the most common form of dementia affecting approximately five million Americans age 65 and older, as well as an estimated 200,000 Americans under the age of 65 who are afflicted with early-onset AD. AD is clinically defined as a progressive neurodegenerative disorder that involves cognitive impairment, memory loss, visual-spatial retrogression and language impairment. AD is the fifth leading cause of death for people age 65 and older.

“Current diagnostic methods are not highly specific,” commented Dr. Sabine Mai, 3DS co-founder and principal inventor. “In addition, AD is only confirmed postmortem pathologically. There is a significant need for an accurate, non-invasive biomarker that can diagnose AD and indicate disease progression, and we believe TeloView™ has the potential to answer that important call.”

In agreement with previous research, the current study demonstrated that TeloViewTM software platform clearly distinguished between AD and non-AD individuals, and between mild, moderate and severe AD, and is, therefore, a promising candidate as a non-invasive AD biomarker and monitoring tool. The current confirmatory study involved a cohort of 44 age- and gender-matched healthy non-caregiver controls and 44 AD study participants. 3D telomeric profiles of buccal cells of AD patients and their non-AD controls were examined with participant information blinded to the analysis.

The Company is currently exploring opportunities to expand the scope of its AD related work with further clinical studies and to fund that work through non-dilutive or independent financing arrangements, such as a joint venture.

About 3DS
3DS (TSXV:DXD; OTCQB:TDSGF; FSE:3D0) is a personalized medicine company with a proprietary software platform based on the three-dimensional analysis of chromosomal signatures. The technology is well developed and supported by 22 clinical studies on over 2,000 patients on 13 different cancers and Alzheimer’s disease. Depending on the desired application, this platform technology can measure the stage of disease, rate of progression of disease, drug efficacy, and drug toxicity. The technology is designed to predict the course of disease and to personalize treatment for the individual patient. For more information, visit the Company’s new website at https://www.3dsignatures.com.

 Forward-Looking Information
This news release includes forward-looking statements that are subject to risks and uncertainties. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of the Company to be materially different from the historical results or from any future results expressed or implied by such forward-looking statements. All statements within, other than statements of historical fact, are to be considered forward looking. Although 3DS believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Risk factors that could cause actual results or outcomes to differ materially from the results expressed or implied by forward-looking information include, among other things: market demand; technological changes that could impact the Company’s existing products or the Company’s ability to develop and commercialize future products; competition; existing governmental legislation and regulations and changes in, or the failure to comply with, governmental legislation and regulations; the ability to manage operating expenses, which may adversely affect the Company’s financial condition; the Company’s ability to successfully maintain and enforce its intellectual property rights and defend third-party claims of infringement of their intellectual property rights; adverse results or unexpected delays in clinical trials; changes in laws, general economic and business conditions; and changes in the regulatory regime. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements. 

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For further information, please contact:

Hugh Rogers

VP Corporate Finance

604-428-8842

investors@3dsignatures.com

OR

Stephen Kilmer

Investor Relations

647-872-4849

stephen.kilmer@3dsignatures.com

The Conversation (0)
×